Low Intensity Focused Ultrasound for Patients With Fibromyalgia
Early Feasibility Study of Low Intensity Focused Ultrasound Neuromodulation in Patients With Fibromyalgia
The overall goal of this study is to establish the safety and feasibility of low intensity transcranial focused ultrasound (liFU) stimulation for patients with fibromyalgia. We will also attempt to investigate the efficacy of liFU for pain and related symptoms and to compare whether liFU effects differ for people trained in different types of meditation.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
Following informed consent (Session 1), participants will participate in a baseline assessment (Session 2), during which they will receive a full battery of questionnaires, as well as a task-based fMRI and a baseline CT scan (the latter used for brain mapping in preparation of the liFU intervention). They will also be randomized during this session. The study is divided into two phases; in Phase 1 they will undergo four virtual sessions of a meditation intervention (either Savoring Meditation or Slow Breathing Meditation), depending on their group allocation (Session 3 to Session 6). They will then receive another assessment composed of questionnaires and a task-based fMRI (Session 7). In Phase 2 they will receive the liFU intervention (Session 8 to Session 11). At Session 11, they will also receive a post-treatment assessment composed of questionnaires and a task-based fMRI. A follow-up assessment (Session 12) four weeks after their final liFU intervention will be composed of questionnaires.
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Claudia Denoue F Postdoctoral Researcher, M.D.
- Номер телефона: (434)-982-2281
- Электронная почта: finanlab@uvahealth.org
Учебное резервное копирование контактов
- Имя: Sierra Clark Clinical Research Coordinator
- Номер телефона: (434)-982-2281
- Электронная почта: finanlab@uvahealth.org
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Females aged 18-75 years
- Physician-confirmed diagnosis of FM according to the 2016 American College of Rheumatology criteria.
- Willingness and ability to comply with scheduled visits and study procedures
Exclusion Criteria:
- History of major neurological disorders
- Current unstable psychiatric disorders or severe current substance use disorders
- Current prescription opioid use or self -reported use of opioids in the past 30 days prior to enrollment (other medications are allowed, but must be on stable dose for at least 4 weeks)
- Contraindications to MRI
- Pregnancy or breastfeeding
- Current neuromodulation therapy
- Current meditation practice
- Current participation in another interventional trial that could confound outcomes
- Cannot read and speak English
- Prisoner or cognitively impaired individuals
- Unwilling or unable to use the internet and/or internet-enabled device to complete study procedures
- Unable or unwilling to comply with study protocols or otherwise determined by the PI to be able to safely participate in the study.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Low Intensity Focused Ultrasound + Savoring Meditation (liFU+SM)
|
In this arm, participants first receive training in Savoring Meditation, a positive affect-focused behavioral intervention designed to enhance positive affect and support chronic pain self-management. Participants complete four 20-minute telehealth training sessions over approximately two weeks delivered by a trained interventionist. After completing the meditation training portion, participants in the liFU + SM arm complete four sessions of low-intensity focused ultrasound targeting the nucleus accumbens during which they actively practice Savoring Meditation concurrent with the sonication.
Другие имена:
|
|
Активный компаратор: Low Intensity Focused Ultrasound
|
In the liFU arm, participants first spend 4 telehealth sessions undergoing training in a slow breathing meditation practice. Subsequently, participants complete four in-person liFU treatment sessions over four weeks, with sequential bilateral sonications targeting the nucleus accumbens during each session. In this arm, participants do not engage in any concurrent meditation practice or other behavioral intervention during sonication. Rather, they only receive liFU sonication during those sessions.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Safety of liFU intervention
Временное ограничение: At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).
|
Number of treatment-related unexpected adverse events and serious adverse events |
At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).
|
|
Study recruitment rate
Временное ограничение: Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).
|
Number of participants enrolled divided by number screened. |
Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).
|
|
Study adherence
Временное ограничение: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).
|
Number of participants to complete all Phase 1 and Phase 2 intervention sessions |
Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).
|
|
Study retention
Временное ограничение: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).
|
Number of enrolled participants retained through the entirety of the study |
Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Nucleus accumbens activation
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
|
Change in blood-oxygen-level-dependent (BOLD) signal in the nucleus accumbens, measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
|
|
Change in nucleus accumbens-ventromedial prefrontal cortex functional connectivity
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
|
Change in functional connectivity between the nucleus accumbens (NAc) and ventromedial prefrontal cortex (vmPFC), measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
|
|
Clinical pain impact
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
Changes in clinical pain impact will be evaluated using the Pain, Enjoyment of life, and General activity (PEG) Scale, which is a hybrid measure of pain severity and pain interference. This scale is comprised of 3 items, each rated on a numerical scale from 0-10. The total score is averaged on a scale from 0-10. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
|
Clinical pain severity
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).
|
Changes in clinical pain severity will be evaluated using the Brief Pain Inventory (BPI). Average pain in the past 24 hours is rated on a scale from 0-10. |
Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).
|
|
Pain catastrophizing
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
Changes in pain catastrophizing will be evaluated using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item scale, each noted on a Likert like scale from 0-4. Total scores are obtained by summing all scores, to obtain a score between 0 and 52. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
|
Fatigue
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
Changes in fatigue levels will be evaluated using the Fatigue Severity Scale (FSS). The FSS is a 9-item scale, each noted on a Likert like scale from 1-7. Total scores are obtained by summing all scores, to obtain a score between 0 and 63. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
|
Fibromyalgia Impact
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
Fibromyalgia Impact will be assessed using the Fibromyalgia Impact Questionnaire Revised (FIQ-R). The FIQ-R is a 21-item scale where each item is rated on a scale from 0-10 and the overall score is calculated as the addition of all items and then normalized relative to a predefined level of importance for each item. Total scores range from 0-100. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
|
Fibromyalgia Severity
Временное ограничение: Assessed at Session 2 (week 0) and Session 7 (week 3).
|
Fibromyalgia Severity will be assessed with the Widespread Pain Index (WPI) and the Symptom Severity Scale (SSS). The WPI counts the number of tender points reported and can range from 0 to 19. The SSS assesses 3 items on a Likert-like scale (from 0-3) as well as 3 items on a binary Yes/No scale (Yes=1, No=0). The SSS scale yields a score ranging from 0-12. In total, the WPI-SSS score is calculated by adding the WPI and the SSS score, yielding a final total score ranging from 0-31. |
Assessed at Session 2 (week 0) and Session 7 (week 3).
|
|
Sleep quality
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
Sleep quality will be assessed using the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI). The ISI is a 7-item Likert-like scale (ranging from 0-4). The total score is obtained by adding all item scores, yielding a total possible range of 0-28. The PSQI is a scale comprising of 7 different components, each of which may range from 0-3. The total score is obtained by adding all component scores, yielding a total possible range of 0-21. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
|
Positive Affect
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
Changes in Positive Affect will be assessed using the Positive and Negative Affect Schedule - Expanded Form (PANAS-X). The PANAS-X consists of 60 items rated on a Likert-like scale (ranging from 1-5). Total scores are separated as General negative affective scores (ranging 10-50), General Positive Affective Scores (ranging 10-50) and a series of emotional scales with varying ranges. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
|
Hedonic Capacity
Временное ограничение: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item scale where each item is rated on a Likert-like scale ranging from 0-3. Total scores are obtained by adding each item, yielding a total score ranging from 0-42. |
Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
|
Соавторы и исследователи
Спонсор
Спонсор
Соавторы
Соавторы
Следователи
Следователи
- Главный следователь: Patrick Finan Finan, PhD, Department of Anesthesiology, University of Virginia
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- HSR 303312
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .